+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Telmisartan Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2025-2034)

  • PDF Icon

    Report

  • 400 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 5805828
The telmisartan market was valued at USD 3.57 Billion in 2024 driven by rising prevalence of hypertension and cardiovascular diseases across the 8 major markets. It is expected to grow at a CAGR of 5.60% during the forecast period 2025-2034 and attain a market value of USD 6.16 Billion by 2034.

Telmisartan Market Overview

Telmisartan is a medication utilized for treating high blood pressure and reducing the risk of cardiovascular conditions, particularly in individuals at high risk, which aids in averting issues such as heart attacks, strokes, and kidney complications. The mechanism involves the inhibition of angiotensin II, leading to the dilation of blood vessels, enhancing circulation, and decreasing strain on the heart.

It is additionally utilized for managing heart failure and protecting the kidneys in diabetic patients. Blocking angiotensin II helps lower blood pressure and enhance blood circulation, promoting heart well-being and safeguarding the kidneys. Possible side effects include feeling dizzy, tired, and getting infections, as well as possible reactions with diuretics, NSAIDs, and specific supplements. Unhealthy lifestyle habits like poor diet, smoking, and lack of physical activity are contributing to the growth in hypertension cases, which is anticipated to boost the market demand in the forecast.

Telmisartan Market Growth Drivers

Rising Prevalence of Hypertension Spurs Market Growth

Hypertension, a common condition with serious health risks, is rising due to factors such as aging populations and unhealthy lifestyle choices. In 2022, the CDC reported that high blood pressure was linked to 685,875 deaths in the United States. Further, it is reported that roughly half the adults have high blood pressure. Telmisartan, an effective blood pressure medication, is widely used to manage hypertension by blocking angiotensin II. Rising awareness of hypertension's dangers is leading to earlier diagnosis and treatment, thereby increasing demand for drugs like telmisartan. Additionally, guidelines recommending aggressive blood pressure management are poised to boost the usage of telmisartan in the coming years.

Telmisartan in Fixed-Dose Combinations (FDCs) is Likely to Augment Demand in the Telmisartan Market

Telmisartan's inclusion in Fixed-Dose Combinations (FDCs) with other drugs like diuretics or calcium channel blockers further boosts its market growth. In May 2024, Akums introduced a new FDC medication, Amlodipine, Telmisartan & Metoprolol (ER) film-coated tablets for resistant hypertension, approved by DCGI. It integrates established medications to effectively control blood pressure. FDCs offer improved therapeutic efficacy, simplified treatment regimens, and enhanced patient compliance, ultimately leading to better long-term blood pressure control and reduced healthcare costs. The growing acceptance of FDCs in medical practice is driving demand for telmisartan-based combinations, solidifying its position in the hypertension market.

Telmisartan Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Growing Awareness about Telmisartan Therapy Set to Impact the Market Landscape Significantly

The rising awareness of the advantages of using telmisartan for treating hypertension and cardiovascular conditions is expanding its market presence. Efforts to encourage early detection and treatment of hypertension are emphasizing the effectiveness of telmisartan in decreasing cardiovascular incidents.

Advancements in Telmisartan Formulations Poised to Boost Telmisartan Market Demand

Pharmaceutical firms are dedicating resources to research and development to enhance telmisartan formulations, such as extended-release types and combinations with other drugs. These advancements improve the absorption of medications and adherence by patients, providing easier treatment alternatives, particularly for older patients with various health issues.

Strategic Collaborations and Partnerships to Elevate the Telmisartan Market Value

Pharmaceutical companies are teaming up and forming alliances to strengthen their position in the telmisartan market through resource and expertise sharing. Collaborating with local partners enables the utilization of their specialized knowledge. Collaborating with research institutes helps create innovative formulas to keep up with the increasing need for hypertension treatments.

Stringent Regulatory Requirements Likely to Amplify Telmisartan Market Size

Strict regulations established by governing bodies such as the FDA and EMA influence the telmisartan market by guaranteeing that safety, effectiveness, and quality criteria are adhered to. Adherence to these rules could result in delays in product releases, yet it is essential for gaining market acceptance. Regulatory changes in nations are becoming more in line with norms, leading to an increase in the request for top-notch telmisartan formulations.

Telmisartan Market Segmentation

“Telmisartan Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Dosage

  • 40 mg
  • 80 mg
  • Others

Market Breakup by Administration

  • Oral
  • Parenteral
  • Others

Market Breakup by Application

  • Hypertension
  • Cardiovascular Disease
  • Others

Market Breakup by Distribution Channel

  • Hospitals Pharmacies
  • Independent Pharmacies
  • Online Pharmacies
  • Others

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Telmisartan Market Share

Market Segmentation Based on the Application to Witness Growth

Based on the application, the market is divided into hypertension, cardiovascular disease, and others. The hypertension application is expected to dominate the market share because of the ability of telmisartan to regulate high blood pressure, a key factor in cardiovascular diseases. Its importance as the initial treatment is vital for patients with conditions such as diabetes or kidney disease. The high demand for telmisartan is also propelled by the elevated occurrence of hypertension, particularly in older populations and areas with lifestyle-related health hazards.

Distribution Channel Segment Holds a Substantial Market Share

Hospital pharmacies, independent pharmacies, online pharmacies, and others are the major distribution channels in the market. Hospital pharmacies are expected to dominate the market due to the large number of prescriptions for high blood pressure and heart conditions coming from hospitals. Hospital pharmacies provide quick access to medications and encourage adherence to treatment plans. Specialized hospital units also guarantee proper administration and monitoring of telmisartan for high-risk groups with complicated medical backgrounds.

Temlisartan Market Analysis by Region

Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.

The United States leads the market share due to the presence of a significant number of older individuals with hypertension and heart problems in the region, who receive assistance from government health programs. Many generic choices are readily accessible, encouraging the use of generic telmisartan medications available at reduced prices.

EU-4 and the United Kingdom are also poised to have a significant market share. Government programs and healthcare systems ensure the availability of telmisartan. Heightened awareness and widespread availability of generic products continue to drive market expansion in the region.

Leading Players in the Telmisartan Market

The key features of the market report include patent analysis, grant analysis, funding, and investment analysis, clinical trials analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:Verdant Life Scie
nces Pvt Ltd Verdant Life Sciences Pvt. Ltd, established in 2008, is a top telmisartan manufacturer in India due to its commitment to improving research capabilities and prioritizing patients' well-being. With the rise in demand for medical services, the company has made a significant mark in the market for its high-quality, life-saving drugs.

Boehringer Ingelheim International GmbH

Boehringer Ingelheim International GmbH is a pharmaceutical company under CH Boehringer Sohn AG & Co KG, which is developing, manufacturing, and marketing pharmaceuticals, parasiticides, vaccines, and therapeutics for unmet medical needs such as human diseases, animal health care, and biopharmaceuticals.

Wellona Pharma

Wellona Pharma, a reputable pharmaceutical manufacturing company in Gujarat, India, has been leading in the production, export, and supply of various pharmaceutical formulations such as tablets, capsules, injections, and more for over a decade. The company specializes in the production of Telmisartan and Amlodipine 80 mg Tablets, used for various medical conditions such as hypertension, coronary artery disease, high blood pressure, and others. Wellona Pharma is known for its high-quality products and quick delivery to clients worldwide, making it a top choice among pharmaceutical manufacturers in India.

Glenmark Pharmaceuticals Inc

Glenmark Pharmaceuticals Limited, headquartered in Mumbai, India, is a multinational company focused on improving patient lives globally. They specialize in innovative/specialty, generics, and OTC products in areas like dermatology, respiratory, and oncology, with a strong presence in diabetes, cardiovascular, and oral contraceptives. Glenmark prioritizes research and development to innovate and address patient needs.

Other players in the market include CTX Lifesciences Pvt Ltd, Atom Pharma, Cerata Pharmaceuticals, Centurion Healthcare, and Scott Morrison.

Key Questions Answered in the Telmisartan Market Report

  • What was the telmisartan market value in 2023?
  • What is the telmisartan market forecast outlook for 2025-2034?
  • What are the regional markets covered in the report?
  • What is the market breakup based on dosage?
  • What is the market segmentation based on application?
  • What is the market segmentation based on distribution channels?
  • What is the market breakup based on the route of administration?
  • What are the major factors aiding the telmisartan market demand?
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the major drivers, opportunities, and restraints in the market?
  • What are the major trends influencing the market?
  • Which regional market is expected to dominate the market share in the forecast period?
  • Which country is likely to experience elevated growth during the forecast period?
  • Who are the key players involved in the telmisartan market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Telmisartan Market Overview - 8 Major Markets
3.1 Telmisartan Market Historical Value (2018-2024)
3.2 Telmisartan Market Forecast Value (2025-2034)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Telmisartan Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Treatment Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Treatment Success Rate
7 Telmisartan Market - Epidemiology Scenario and Forecast - 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2018-2034)
7.1.1 Prevalence, by Country
7.1.1.1 United States
7.1.1.2 United Kingdom
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Diagnosed Cases, by Country
7.1.2.1 United States
7.1.2.2 United Kingdom
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate, by Country
7.1.3.1 United States
7.1.3.2 United Kingdom
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Telmisartan Market Landscape - 8 Major Markets
8.1 Telmisartan Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Telmisartan Market: Product Landscape
8.2.1 Analysis by Dosage
8.2.2 Analysis by Route of Administration
8.2.3 Analysis by Application
9 Telmisartan Market Challenges and Unmet Needs
9.1 Treatment Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Treatment
11 Telmisartan Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Telmisartan Market Segmentation (218-2034) - 8 Major Markets
12.1 Telmisartan Market (2018-2034) by Dosage
12.1.1 Market Overview
12.1.2 40 mg
12.1.3 80 mg
12.1.4 Others
12.2 Telmisartan Market (2018-2034) by Route of Administration
12.2.1 Market Overview
12.2.2 Oral
12.2.3 Parenteral
12.2.4 Others
12.3 Telmisartan Market (2018-2034) by Application
12.3.1 Market Overview
12.3.2 Hypertension
12.3.3 Cardiovascular Disease
12.3.4 Others
12.4 Telmisartan Market (2018-2034) by Distribution Channel
12.4.1 Market Overview
12.4.2 Hospitals Pharmacies
12.4.3 Independent Pharmacies
12.4.4 Online Pharmacies
12.4.5 Others
12.5 Telmisartan Market (2018-2034) by Region
12.5.1 Market Overview
12.5.2 United States
12.5.3 EU-4 and the United Kingdom
12.5.3.1 Germany
12.5.3.2 France
12.5.3.3 Italy
12.5.3.4 Spain
12.5.3.5 United Kingdom
12.5.4 Japan
12.5.5 India
13 United States Telmisartan Market (218-2034)
13.1 United States Telmisartan Market Historical Value (2018-2024)
13.2 United States Telmisartan Market Forecast Value (2025-2034)
13.3 United States Telmisartan Market (2018-2034) by Dosage
13.3.1 Market Overview
13.3.2 40 mg
13.3.3 80 mg
13.3.4 Others
13.4 United States Telmisartan Market (2018-2034) by Route of Administration
13.4.1 Market Overview
13.4.2 Oral
13.4.3 Parenteral
13.4.4 Others
13.5 United States Telmisartan Market (2018-2034) by Application
13.5.1 Market Overview
13.5.2 Hypertension
13.5.3 Cardiovascular Disease
13.5.4 Others
13.6 United States Telmisartan Market (2018-2034) by Distribution Channel
13.6.1 Market Overview
13.6.2 Hospitals Pharmacies
13.6.3 Independent Pharmacies
13.6.4 Online Pharmacies
13.6.5 Research Laboratories
13.6.6 Others
14 EU-4 and United Kingdom Telmisartan Market (218-2034)
14.1 EU-4 and United Kingdom Telmisartan Market Historical Value (2018-2024)
14.2 EU-4 and United Kingdom Telmisartan Market Forecast Value (2025-2034)
14.3 EU-4 and United Kingdom Telmisartan Market (2018-2034) by Dosage
14.3.1 Market Overview
14.3.2 40 mg
14.3.3 80 mg
14.3.4 Others
14.4 EU-4 and United Kingdom Telmisartan Market (2018-2034) by Route of Administration
14.4.1 Market Overview
14.4.2 Oral
14.4.3 Parenteral
14.4.4 Others
14.5 EU-4 and United Kingdom Telmisartan Market (2018-2034) by Application
14.5.1 Market Overview
14.5.2 Hypertension
14.5.3 Cardiovascular Disease
14.5.4 Others
14.6 EU-4 and United Kingdom Telmisartan Market (2018-2034) by Distribution Channel
14.6.1 Market Overview
14.6.2 Hospitals Pharmacies
14.6.3 Independent Pharmacies
14.6.4 Online Pharmacies
14.6.5 Research Laboratories
14.6.6 Others
15 Japan Telmisartan Market
15.1 Japan Telmisartan Market Historical Value (2018-2024)
15.2 Japan Telmisartan Market Forecast Value (2025-2034)
15.3 Japan Telmisartan Market (2018-2034) by Dosage
15.3.1 Market Overview
15.3.2 40 mg
15.3.3 80 mg
15.3.4 Others
15.4 Japan Telmisartan Market (2018-2034) by Route of Administration
15.4.1 Market Overview
15.4.2 Oral
15.4.3 Parenteral
15.4.4 Others
15.5 Japan Telmisartan Market (2018-2034) by Application
15.5.1 Market Overview
15.5.2 Hypertension
15.5.3 Cardiovascular Disease
15.5.4 Others
15.6 Japan Telmisartan Market (2018-2034) by Distribution Channel
15.6.1 Market Overview
15.6.2 Hospitals Pharmacies
15.6.3 Independent Pharmacies
15.6.4 Online Pharmacies
15.6.5 Research Laboratories
15.6.6 Others
16 India Telmisartan Market
16.1 India Telmisartan Market Historical Value (2018-2024)
16.2 India Telmisartan Market Forecast Value (2025-2034)
16.3 India Telmisartan Market (2018-2034) by Dosage
16.3.1 Market Overview
16.3.2 40 mg
16.3.3 80 mg
16.3.4 Others
16.4 India Telmisartan Market (2018-2034) by Route of Administration
16.4.1 Market Overview
16.4.2 Oral
16.4.3 Parenteral
16.4.4 Others
16.5 India Telmisartan Market (2018-2034) by Application
16.5.1 Market Overview
16.5.2 Hypertension
16.5.3 Cardiovascular Disease
16.5.4 Others
16.6 India Telmisartan Market (2018-2034) by Distribution Channel
16.6.1 Market Overview
16.6.2 Hospitals Pharmacies
16.6.3 Independent Pharmacies
16.6.4 Online Pharmacies
16.6.5 Research Laboratories
16.6.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 Japan PMDA
17.5 India CDSCO
17.6 Others
18 Patent Analysis
18.1 Analysis by Cancer Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Grants Analysis
20.1 Analysis by Year
20.2 Analysis by Amount Awarded
20.3 Analysis by Issuing Authority
20.4 Analysis by Grant Application
20.5 Analysis by Funding Institute
20.6 Analysis by NIH Departments
20.7 Analysis by Recipient Organization
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Dosage of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Strategic Initiatives
22.1 Analysis by Partnership Instances
22.2 Analysis by Dosage of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Market Share Analysis, By Region (Top 5 Companies)
23.2 CTX Lifesciences Pvt Ltd.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Companies News and Developments
23.2.5 Certifications
23.3 Verdant Life Sciences Pvt Ltd
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Companies News and Developments
23.3.5 Certifications
23.4 Boehringer Ingelheim International GmbH
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Companies News and Developments
23.4.5 Certifications
23.5 Atom pharma
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Companies News and Developments
23.5.5 Certifications
23.6 Cerata Pharmaceuticals
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Companies News and Developments
23.6.5 Certifications
23.7 Centurion Healthcare
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Companies News and Developments
23.7.5 Certifications
23.8 Wellona Pharma
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Companies News and Developments
23.8.5 Certifications
23.9 Glenmark Pharmaceuticals Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Companies News and Developments
23.9.5 Certifications
23.10 Scott Morrison
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Companies News and Developments
23.10.5 Certifications
24 Telmisartan Treatment Drugs - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket

Companies Mentioned

  • Boehringer Ingelheim International GmbH
  • Wellona Pharma
  • Glenmark Pharmaceuticals Inc.

Table Information